2024
The Therapeutic Role of Intermittent Theta Burst Stimulation in Schizophrenia
Salabat D, Pourebrahimi A, Mayeli M, Cattarinussi G. The Therapeutic Role of Intermittent Theta Burst Stimulation in Schizophrenia. Journal Of Ect 2024, 40: 78-87. PMID: 38277616, DOI: 10.1097/yct.0000000000000972.Peer-Reviewed Original ResearchConceptsPositive and Negative Syndrome ScaleIntermittent theta burst stimulationDorsolateral prefrontal cortexTheta burst stimulationPrefrontal cortexPositive and Negative Syndrome Scale positive scoreNegative scoresPANSS total scoreNegative Syndrome ScalePANSS negative scoresHigh-frequency formsBurst stimulationTarget brain regionsEffects of intermittent theta burst stimulationPositive symptomsSyndrome ScaleSchizophrenia symptomsTranscranial magnetic stimulationBrain regionsResistant to adverse effectsTotal scoreSchizophreniaGeneral scoreMidline cerebellumMeta-analysis
2023
Victimization in schizophrenia and its relation to violence
Buchanan A, Stefanovics E, Rosenheck R. Victimization in schizophrenia and its relation to violence. Schizophrenia Research 2023, 255: 52-58. PMID: 36963231, DOI: 10.1016/j.schres.2023.03.018.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialMental health symptomsStudy entryCross-sectional designAntipsychotic treatmentEffectiveness trialSchizophrenia symptomsMultivariate analysisHealth symptomsSchizophreniaViolent behaviorSubstance useSymptomsRecent victimizationPotential causesAggressive behaviorChildhood experiencesBaselineMore incidentsCorrelatesTreatmentVictims of violenceSexual abuseClose friendsMost perpetratorsAssociations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls
Lin B, Vermeulen J, Bolhuis K, Chang X, Schirmbeck F, van Eijk K, investigators G, Alizadeh B, Bartels-Velthuis A, van Amelsvoort T, Bruggeman R, Cahn W, de Haan L, Rutten B, Guloksuz S, Luykx J, van Os J, Simons C, van Winkel R, Guloksuz S, Blankers M, van den Brink W, de Haan L, Luykx J. Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research 2023, 323: 115143. PMID: 36948018, DOI: 10.1016/j.psychres.2023.115143.Peer-Reviewed Original ResearchConceptsHealthy controlsSmoking behaviorPsychotic symptomsSchizophrenia symptomsUnaffected siblingsProspective cohort studySix-year followMental health symptomsSymptom dimensionsCohort studyRisk factorsDepressive symptomsPsychotic disordersPatientsPositive symptomsHealth symptomsNegative symptomsSimilar effect sizesSymptomsLinear mixed-effects modelsMixed-effects modelsGenetic riskMean numberPolygenic scoresOverall sample
2016
Correction to Kane et al. (2016)
Kane M, Meier M, Smeekens B, Gross G, Chun C, Silvia P, Kwapil T. Correction to Kane et al. (2016). Journal Of Experimental Psychology General 2016, 145: 1603-1603. PMID: 27935733, DOI: 10.1037/xge0000248.Peer-Reviewed Original ResearchExecutive controlExecutive deficitsMind wanderingAttention constraintsIndividual-differences structureMind-wandering propensityLarge correlational studyLatent variable approachExecutive attentionParanoid schizotypyAttentional constraintsNegative schizotypyIndividual differencesAttention controlSeparable constructsMemory capacityExecutive failureMultidimensional constructSchizotypyWMCCorrelational studySchizophrenia symptomsSchizophreniaConstructsM. GrossIndividual Differences in the Executive Control of Attention, Memory, and Thought, and Their Associations With Schizotypy
Kane M, Meier M, Smeekens B, Gross G, Chun C, Silvia P, Kwapil T. Individual Differences in the Executive Control of Attention, Memory, and Thought, and Their Associations With Schizotypy. Journal Of Experimental Psychology General 2016, 145: 1017-1048. PMID: 27454042, PMCID: PMC4965188, DOI: 10.1037/xge0000184.Peer-Reviewed Original ResearchConceptsExecutive deficitsMind wanderingAttention constraintsIndividual-differences structureMind-wandering propensityLarge correlational studyLatent variable approachExecutive attentionParanoid schizotypyExecutive controlAttentional constraintsNegative schizotypyAttention controlSeparable constructsMemory capacityExecutive failureMultidimensional constructWMCSchizotypyCorrelational studySchizophrenia symptomsSchizophreniaConstructsTaskDeficits
2014
Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China
Mohamed S, Rosenheck R, He H, Yuping N. Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China. Social Psychiatry And Psychiatric Epidemiology 2014, 49: 1063-1070. PMID: 24549835, DOI: 10.1007/s00127-014-0824-1.Peer-Reviewed Original ResearchConceptsDrug Attitude InventorySchizophrenia symptomsPsychiatric hospitalOverall severityMeasures of insightGuangzhou Psychiatric HospitalTime of admissionBenefits of medicationsLarge psychiatric hospitalNegative Syndrome ScaleTreatment Attitudes QuestionnaireSymptoms of schizophreniaAcceptance of medicationHospitalized patientsAntipsychotic treatmentDAI scoresChronic schizophreniaMedicationsAnalysis of covarianceSyndrome ScaleMental illnessBivariate analysisSymptomsLarger studySchizophrenia
2009
Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol
R. A, Hounie A, Sampaio A, Arrais J, Miguel E, Elkis H. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Comprehensive Psychiatry 2009, 50: 437-442. PMID: 19683614, DOI: 10.1016/j.comppsych.2008.11.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsAntipsychotic AgentsClozapineComorbidityDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHaloperidolHumansInterview, PsychologicalMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSchizophreniaYoung AdultConceptsObsessive-compulsive disorderObsessive-compulsive symptomsSchizophrenia patientsPrevalence of OCDSchizophrenia rating scalesPresence of OCSPrevalence of patientsUse of clozapineUse of antidepressantsClinical Global ImpressionPANSS total scoreCross-sectional studyStructured Clinical InterviewHigher severity scoresNegative Syndrome ScaleHigher severityYale-Brown ObsessiveGlobal ImpressionSeverity scorePatientsClozapineClinical InterviewHaloperidolSchizophrenia symptomsSyndrome Scale
2008
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptoms
2006
Enhanced Sensitivity to the Euphoric Effects of Alcohol in Schizophrenia
D'Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T, Zimolo Z, Gueorguieva R, Krystal JH. Enhanced Sensitivity to the Euphoric Effects of Alcohol in Schizophrenia. Neuropsychopharmacology 2006, 31: 2767-2775. PMID: 16985503, DOI: 10.1038/sj.npp.1301207.Peer-Reviewed Original ResearchConceptsEffects of alcoholHealthy subjectsBlood alcohol levelsPositive psychotic symptomsSmall transient increaseSelf-medication hypothesisPerceptual alterationsAlcohol administrationMotor functionAlcohol dosesElevated riskPsychotic symptomsLifetime exposureSchizophrenia patientsSchizophrenia symptomsEuphoric effectsNegative symptomsAlcohol levelsAlcohol useStimulatory effectSubjective effectsTransient increaseSchizophreniaStimulatory responseAlcohol responsesSpecial Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia
Chwastiak L, Rosenheck R, McEvoy J, Keefe R, Swartz M, Lieberman J. Special Section on CATIE Baseline Data: Interrelationships of Psychiatric Symptom Severity, Medical Comorbidity, and Functioning in Schizophrenia. Psychiatric Services 2006, 57: 1102-1109. PMID: 16870960, DOI: 10.1176/ps.2006.57.8.1102.Peer-Reviewed Original ResearchConceptsMedical comorbiditiesMedical conditionsPsychiatric symptom severityPsychosocial functioningNeurocognitive impairmentSchizophrenia symptomsBaseline dataSymptom severityCross-sectional studyPhysical health statusSample of patientsClinical Antipsychotic TrialsPoorer neurocognitive functioningGreater depressive symptomsSevere schizophrenia symptomsSample of personsDiabetes mellitusAntipsychotic pharmacotherapyIndependent associationAntipsychotic TrialsMultivariate regression modelComorbiditiesPsychotic symptomsDepressive symptomsHealth status
2005
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza D, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57: 594-608. PMID: 15780846, DOI: 10.1016/j.biopsych.2004.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAkathisia, Drug-InducedArousalCognitionDose-Response Relationship, DrugDouble-Blind MethodDronabinolEndocrine SystemFemaleHumansInjections, IntravenousMaleMental RecallMiddle AgedMotor ActivityNeuropsychological TestsPerceptionPsychiatric Status Rating ScalesPsychotic DisordersPsychotropic DrugsSchizophreniaVerbal LearningConceptsSchizophrenia patientsAntipsychotic-treated schizophrenia patientsDelta-9-tetrahydrocannabinol effectsLong-term adverse eventsCognitive deficitsPlacebo-controlled studyDelta-9-THCTransient exacerbationAdverse eventsReceptor dysfunctionEndocrine effectsHealthy subjectsStudy participationPsychotic disordersPlasma prolactinSchizophrenia symptomsPatientsSchizophreniaCognitive effectsPerceptual alterationsDeficitsCannabisSubjectsAkathisiaExacerbation
2003
Trauma and Posttraumatic Stress Disorder in People With Schizophrenia
Resnick SG, Bond GR, Mueser KT. Trauma and Posttraumatic Stress Disorder in People With Schizophrenia. Journal Of Psychopathology And Clinical Science 2003, 112: 415-423. PMID: 12943020, DOI: 10.1037/0021-843x.112.3.415.Peer-Reviewed Original ResearchConceptsPTSD symptomsPosttraumatic stress disorder (PTSD) severityLifetime trauma historyPosttraumatic stress disorderGreater emotional distressPTSD interventionsThreat of harmStress disorderSubjective distressCurrent PTSDTrauma historyEmotional distressPTSDDisorder severityLife threatSchizophrenia symptomsSymptom InterviewDistressSchizophreniaTotal sampleGreater severitySchizophrenia severityTraumaRoutine assessmentClients
2002
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms
Abi-Saab W, Seibyl JP, D'Souza C, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162: 55-62. PMID: 12107618, DOI: 10.1007/s00213-002-1057-7.Peer-Reviewed Original ResearchConceptsReceptor antagonismSchizophrenic patientsNeuroleptic-free schizophrenic patientsBrief Psychiatric Rating ScaleDouble-blind conditionsPsychiatric Rating ScaleTest dayRitanserin pretreatmentIntravenous infusionReceptor modulationAntipsychotic activityMale inpatientsReceptor stimulationPlasma prolactinCortisol levelsSchizoaffective disorderSchizophrenia symptomsPositive symptomsNegative symptomsRandomized orderPatientsRating ScaleBehavioral activationSymptomsRitanserin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply